Ipamorelin vs Sermorelin vs CJC-1295: Triple GH Peptide Comparison

The GH Axis: Two Entry Points

Growth hormone release is controlled by two opposing hypothalamic signals:

• GHRH (Growth Hormone-Releasing Hormone) — stimulates GH release from the pituitary
• Somatostatin — inhibits GH release

Additionally, a separate receptor system — the ghrelin receptor (GHSR) — can stimulate GH release independently.

Understanding which receptor a peptide targets explains most of the differences in how these three compounds work:

• CJC-1295 and Sermorelin: GHRH analogs — bind GHRH receptors
• Ipamorelin: GHRP (growth hormone-releasing peptide) — binds ghrelin receptors (GHSR-1a)

Sermorelin

Sermorelin is a synthetic 29-amino acid fragment of GHRH — the first 29 amino acids, which represent the biologically active portion. It was FDA-approved for growth hormone deficiency in children before being discontinued for commercial reasons.

Key characteristics:

• Short half-life (~10–20 minutes) — produces a physiological GH pulse that mirrors natural release
• Requires intact pituitary function — doesn’t work if the pituitary is severely damaged
• GH release is still modulated by somatostatin — can be blunted if somatostatin tone is high
• Well-studied safety profile from clinical use
• Does not significantly increase cortisol, prolactin, or other pituitary hormones

View Sermorelin →

CJC-1295

CJC-1295 is a modified GHRH analog engineered for dramatically extended half-life. The standard version (CJC-1295 with DAC — Drug Affinity Complex) binds to albumin in the blood, extending its half-life to 6–8 days.

Key characteristics:

• Long half-life means sustained GHRH receptor stimulation rather than pulsatile release
• Produces “GH bleed” — chronic elevation of GH rather than sharp peaks
• Research shows 2–10 fold increases in GH and 1.5–3 fold increases in IGF-1 in clinical studies
• Often combined with Ipamorelin because the two peptides work on different receptors synergistically
• Longer duration means less frequent administration

Ipamorelin

Ipamorelin is a selective GHRP (growth hormone-releasing peptide) — one of the most selective GHSRs (ghrelin receptor agonists) developed. It stimulates GH release through the ghrelin receptor system, completely independently of the GHRH pathway.

Key characteristics:

• Produces sharp, physiological GH pulses (like Sermorelin) with short half-life (~2 hours)
• Highly selective — unlike GHRP-2 and GHRP-6, Ipamorelin causes minimal cortisol or prolactin release
• Can overcome somatostatin suppression that would blunt GHRH analogs
• Synergistic with CJC-1295 — the combination activates both GH release pathways simultaneously
• Does not significantly stimulate appetite (unlike GHRP-6)

View CJC-1295/Ipamorelin Blend →

Head-to-Head Comparison

Which Is Best for Research?

There’s no single answer — it depends on what you’re studying:

• Sermorelin is best for studying physiological GH pulsatility and pituitary responsiveness — it mirrors natural GHRH signaling most closely and has the cleanest clinical safety data
• CJC-1295 with DAC is useful for sustained IGF-1 elevation research due to its extended duration
• Ipamorelin is best for selective GH stimulation studies where you want to avoid cortisol/prolactin interference
• CJC-1295 + Ipamorelin combination is widely used when the research goal is maximal GH output through dual-pathway activation

Written by the NorthPeptide Research Team

Key Research References